(Nanostics) From the launch of Nanostics clinical validation study for ClarityDX Prostate, recruitment of men increased significantly in November, pushing the number of men enrolled over 200. This coincided with the ‘Grow a Mo’ (mustache) campaign from the global charity Movember and Alberta Cancer Foundation’s Giving Tuesday 2019 campaign. Funding support to develop our novel blood screening test for early diagnosis of clinically significant prostate cancer continues to come from generous donors through the Alberta Cancer Foundation.

Original source: https://www.eurekalert.org/pub_releases/2019-12/n-pcs120319.php